241. Evaluation of clinical interventions made by pharmacists in chemotherapy preparationLea Knez, Raisa Laaksonen, Catherine Duggan, 2010, izvirni znanstveni članek Povzetek: Background. Cancer drugs are high risk drugs and medication errors in their prescribing, preparation and administration have serious consequences, including death. The importance of a multidisciplinary approach and the benefits of pharmacistsć contribution to cancer treatment to minimise risk have been established. However, the impact of services provided by pharmaciststo cancer patient care is poorly studied. This study explored the clinical interventions made by pharmacists in dispensing of chemotherapy doses, and evaluated pharmacistsć contribution to patient care. Methods. Pharmacists at the Chemotherapy Preparation Unit at a tertiary cancer centre in London were shadowed by two research pharmacists during the clinical screening of chemotherapy prescriptions and release of prepared drugs. An expert panel of pharmacy staff rated the clinical significance of the recordedinterventions. Results. Twenty-one pharmacistsć interventions were recorded during the screening or releasing of 130 prescriptions or drugs. ĆDrug and therapyĆ (38%), ĆclericalĆ (22%) and Ćdose, frequency and durationĆ (19%) related problems most often required an intervention, identifying areas in chemotherapy prescribing that need improvement. The proposed recommendations were implemented in 86% of the cases. Many recorded interventions (48%) were ranked to have had a Ćvery significantĆ influence on patient care. Conclusion. Clinical interventions made by pharmacists had a significant impact on patient care. The integration of pharmacistsć technical and clinical roles into dispensing of chemotherapy doses is required for providing high-quality cancer services.
Objavljeno v DiRROS: 18.03.2024; Ogledov: 121; Prenosov: 32
 Celotno besedilo (452,60 KB) |
242. Antigen expression on recurrent meningioma cellsAndrej Vranič, 2010, izvirni znanstveni članek Povzetek: Introduction. Meningiomas are intracranial brain tumours that frequently recur. Recurrence rates up to 20% in 20 years for benign meningiomas, up to 80% for atypical meningiomas and up to 100% for malignant meningiomas, have been reported. The most important prognostic factors for meningioma recurrenceare meningioma grade, meningioma invasiveness and radicality of neurosurgical resection. The aim of our study was to evaluate the differences in antigenic expression on the surface of meningioma cells between recurrent and non-recurrent meningiomas. Methods. 19 recurrent meningiomas and 35 non-recurrent meningiomas were compared regarding the expression of MIB-1 antigen, progesterone receptors, cathepsin B and cathepsin L, using immunohistochemistry. Results. MIB-1 antigen expression was higher in the recurrent meningioma group (p=0.001). No difference in progesterone receptor status between recurrent and non-recurrent meningiomas was confirmed. Immunohistochemical intensity scores for cathepsin B (p= 0.007) and cathepsin L (p<0.001) were both higher in the recurrent than in the non-recurrent meningioma group. Conslusions. MIB-1 antigen expression is higher in recurrentcompared to non-recurrent meningiomas. There is no difference in expression of progesterone receptors between recurrent and non-recurrent meningiomas. Cathepsins B and L are expressed more in recurrent meningiomas.
Objavljeno v DiRROS: 15.03.2024; Ogledov: 150; Prenosov: 33
Celotno besedilo (956,01 KB) |
243. Study of radiation induced changes of phosphorus metabolism in mice by ▫$^{31}P$▫ NMR spectroscopyIgor Serša, Simona Kranjc Brezar, Gregor Serša, Alenka Nemec Svete, Bojan Ložar, Ana Sepe, Jernej Vidmar, Marjeta Šentjurc, 2010, izvirni znanstveni članek Objavljeno v DiRROS: 15.03.2024; Ogledov: 132; Prenosov: 38
Celotno besedilo (699,32 KB) |
244. |
245. |
246. Genetic markers in oligodendroglial tumoursTomaž Velnar, Uroš Smrdel, Mara Popović, Gorazd Bunc, 2010, pregledni znanstveni članek Povzetek: Background. Oliogodendrogliomas are brain tumours composed of the cells resembling oligodendrocytes. They represent the third most common glial tumour, comprising 2.5% of all primary brain tumours and 5-20% of all gliomas. Conclusions. Oligodendroglial tumours with 1p and 19q loss demonstrate a better overall prognosis due to more indolent clinical behaviour and higher sensitivity to treatment. Additionally, 1p and 19q loss is a marker of clinical utility, helping to assess tumour sensitivity to chemotherapy and harbouring the potential for improving the diagnosis and survival of oligodendroglioma patients as well as future clinical practice.
Objavljeno v DiRROS: 15.03.2024; Ogledov: 124; Prenosov: 32
Celotno besedilo (616,34 KB) |
247. |
248. |
249. |
250. |
